Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Gains from Sales and Divestitures (2016 - 2019)

Akebia Therapeutics has reported Gains from Sales and Divestitures over the past 4 years, most recently at $323136.0 for Q4 2019.

  • Quarterly Gains from Sales and Divestitures fell 60.52% to $323136.0 in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $323136.0 through Dec 2019, down 60.52% year-over-year, with the annual reading at $323136.0 for FY2019, 60.52% down from the prior year.
  • Gains from Sales and Divestitures was $323136.0 for Q4 2019 at Akebia Therapeutics, down from $818395.0 in the prior quarter.
  • Over five years, Gains from Sales and Divestitures peaked at $818395.0 in Q4 2018 and troughed at $90566.0 in Q4 2017.
  • The 4-year median for Gains from Sales and Divestitures is $215912.0 (2016), against an average of $335196.2.
  • Year-over-year, Gains from Sales and Divestitures surged 803.64% in 2018 and then crashed 60.52% in 2019.
  • A 4-year view of Gains from Sales and Divestitures shows it stood at $108688.0 in 2016, then dropped by 16.67% to $90566.0 in 2017, then surged by 803.64% to $818395.0 in 2018, then plummeted by 60.52% to $323136.0 in 2019.
  • Per Business Quant, the three most recent readings for AKBA's Gains from Sales and Divestitures are $323136.0 (Q4 2019), $818395.0 (Q4 2018), and $90566.0 (Q4 2017).